April 15, 2019

Australis Capital DTC Eligibility Update

Australis Capital Inc. is pleased to announce the Company has been approved for DTC eligibility for its common shares traded on the OTCQB exchange under symbol "AUSAF".
March 25, 2019

Australis Capital Spring Investor Summit Update

Australis Capital Inc. today announced that the Company is unable to present at the Spring Investor Summit in New York City on April 2, 2019. The Company is attending the event and will be scheduling one-on-one investor meetings April 1-2.
March 14, 2019

Australis Capital to Participate in 31st Annual ROTH Conference

Australis Capital Inc. today announced that Michael Carlotti, the Company's Chief Financial Officer and Cleve Tzung, SVP, Mergers and Acquisitions, will be attending and meeting with investors at the ROTH Conference 2019, to be held March 17-19, 2019, at the Ritz-Carlton, Laguna Niguel, CA.
February 26, 2019

Australis Capital to Acquire California Cannabis Brand Mr. Natural Productions, Inc.

LAS VEGAS, Feb. 26, 2019 /CNW/ - Australis Capital Inc. (CSE: AUSA)(OTCQB: AUSAF) ("Australis" or the "Company") is pleased to announce the Company has acquired 100% of Mr. Natural Productions, Inc., ("Mr. Natural") a multiple award-winning medical and recreational cannabis brand based in California.
February 6, 2019

Australis Capital Commences Trading on the OTCQB Market in the United States

LAS VEGAS, Feb. 6, 2019 /CNW/ - Australis Capital Inc. (CSE: AUSA OTC: AUSAF) ("Australis" or the "Company") is pleased to announce that the Company's common shares have commenced trading on the OTCQB® Venture Market under the ticker symbol "AUSAF".  The Company will continue to trade on the Canadian Securities Exchange (the "CSE") under the symbol "AUSA".
January 14, 2019

Australis Capital Invests in Folium Biosciences a Global Leader in Non-Psychoactive Cannabinoid Production

LAS VEGAS, Jan. 14, 2019 /CNW/ - Australis Capital Inc. (CSE: AUSA) ("Australis" or the "Company") is pleased to announce the Company has invested $3,000,000 USD in Folium Biosciences ("Folium"), the largest vertically integrated producer, manufacturer, and distributor of hemp-derived phytocannabinoids in the United States. Folium also owns and operates the largest phytocannabinoid extraction and purification facility in the United States, with plans for a new pharmaceutical division and the completion of their Canadian facility in 2019.